Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely
Mandate

Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely

March 08, 2022 Employment and Benefits Insurance Law IT, Telecommunications and Outsourcing M&A Corporate Crime & Compliance Financial Regulatory Intellectual Property

Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely. Insurely offers a digital platform which gives insurance policyholders easy access to an overview of their insurance policies.

Vinge’s team consisted of Christina Kokko, Johan Larsson, Isabelle Wållgren and Nando Basic (M&A), Viveka Classon and Elin Samara (Insurance regulatory), Fredrika Hjelmberg (IT), Nicklas Thorgerzon (GDPR), Elin Broman (Employment), Axel Lennartsson (IPR), Tove Tullberg (Compliance) and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025